Sponsored By

For information on becoming a sponsor or exhibitor, please click here.


OCT 10 - 11 2018 Opens: 6:00 AM PT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Cancer Research & Oncology 2018

14 8 2828

The 6th Annual Cancer Research & Oncology Virtual Event will take place October 10-11, 2018. The free, two-day online event will bring research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots event, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

Cancer Research & Oncology 2018 will address a range of topics, such as:

  • Cancer vaccines
  • Immunotherapy and other therapeutics
  • Analysis of tumor growth
  • Immunogenic cell death in cancer: the quantity/quality conundrum”
  • Biomarker discovery from big pharmacogenomic data
  • Cancer epigenetics
    • Genetic markers / Biomarkers
  • Organ-specific cancers
    • ENT / Thyroid
    • Breast
    • Colon
    • Lung
    • Multiple Myelomas
    • Neuro-oncology

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.


Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2018 Cancer Research and Oncology Virtual Event. Submission is free. Submit your abstract here

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE). To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRcancer to follow the conversation!


Speakers:
  • Program Director, National Science Foundation
  • Post-Doctoral Fellow, Princess Margaret Cancer Research, University Health Network
  • Assistant Professor, Weill Cornell Medical College/New York Presbyterian
  • Assistant Professor, Princess Margaret Cancer Center, University of Toronto
  • Professor, Mayo Clinic
  • Post Doctoral Research Scholar at University of California, San Francisco
  • Professor of Pediatrics, Department of Human Oncology & Genetics, University of Wisconsin-Madison
  • Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center
  • Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
  • Medical Director, Head and Neck Oncology, Massachusetts General Hospital

Show Resources
Agenda
  • OCT 10, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immunogenic Cell Death in Cancer: The Quantity/Quality Conundrum
    Speaker: Lorenzo Galluzzi, PhD
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovery of Biomarkers Predictive of Anticancer Drug Response in Preclinical Settings
    Speaker: Benjamin Haibe-Kains, PhD
  • OCT 11, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Homing in on RET; New Precision Medicine Approaches in RET-Driven Cancers
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
  • OCT 10, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immunogenic Cell Death in Cancer: The Quantity/Quality Conundrum
    Speaker: Lorenzo Galluzzi, PhD
  • OCT 10, 2018 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Discovery of Biomarkers Predictive of Anticancer Drug Response in Preclinical Settings
    Speaker: Benjamin Haibe-Kains, PhD
  • OCT 11, 2018 06:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Homing in on RET; New Precision Medicine Approaches in RET-Driven Cancers
  • OCT 11, 2018 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Krastan Blagoev
    Program Director, National Science Foundation
  • Jason De Melo, PhD
    Post-Doctoral Fellow, Princess Margaret Cancer Research, University Health Network
  • Lorenzo Galluzzi, PhD
    Assistant Professor, Weill Cornell Medical College/New York Presbyterian
    Biography
      Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College (New York, USA), and Honorary Associate Professor at the Faculty of Medicine of the Paris Descartes University (Paris, France). Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team "Apoptosis, Cancer and Immunity" at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 350 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007-2013). Lorenzo Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Section Chief Editor for Oncotarget (Autophagy and Cell Death section), Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease.
    • Benjamin Haibe-Kains, PhD
      Assistant Professor, Princess Margaret Cancer Center, University of Toronto
      Biography
        Benjamin Haibe-Kains is a Scientist at the Princess Margaret Cancer Centre (PM), University Health Network, and Assistant Professor in the Medical Biophysics and Computer Science departments of the University of Toronto. Dr. Haibe-Kains earned his PhD in Bioinformatics at the Université Libre de Bruxelles (Belgium), for which he was awarded a Solvay Award (Belgium). Supported by a Fulbright Award, Dr. Haibe-Kains did his postdoctoral fellowship at the Dana-farber Cancer Institute and Harvard School of Public Health (USA). Dr. Haibe-Kains started his own laboratory at the Institut de Recherches Cliniques de Montréal (Canada) and moved to PM in November 2013. Dr. Haibe-Kains' research focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of carcinogenesis. Dr. Haibe-Kains and his team are analyzing high-throughput (pharmaco)genomic datasets to develop new prognostic and predictive models and to discover new therapeutic regimens in order to significantly improve disease management. Dr. Haibe-Kains' main scientific contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
      • Keith Knutson, PhD
        Professor, Mayo Clinic
      • Khyati Shah, PhD
        Post Doctoral Research Scholar at University of California, San Francisco
        Biography
          Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
        • Paul Sondel, MD, PhD
          Professor of Pediatrics, Department of Human Oncology & Genetics, University of Wisconsin-Madison
        • Jennifer Wargo, MD
          Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center
          Biography
            Dr. Wargo's career commitment is to advance the understanding and treatment of disease through science. After completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital/Harvard Medical School where... she became interested in the biology and treatment of cancer. During her training, she completed 2 fellowships in surgical oncology with a focus on immunotherapy for cancer. Dr. Wargo was recruited to the Division of Surgical Oncology at Massachusetts General Hospital in July 2008 and had an active research laboratory focusing on melanoma tumorigenesis and immunotherapy for cancer. One exciting finding involved data describing the effect of BRAF-targeted therapy on tumor antigen expression in melanoma as a basis for combining targeted therapy and immunotherapy in the treatment of this disease. Dr. Wargo validated those findings in patients treated with BRAF inhibitors. She has continued critical studies to better understand the effects of BRAF inhibition on immune responses in melanoma, and established a unique set of serial tumor biopsies and blood samples from patients enrolled on clinical trials on BRAF inhibitors. Through analysis of these samples, she contributed significantly to the world literature regarding resistance mechanisms and the effect of targeted therapy on anti-tumor immunity. Dr. Wargo was recruited to MD Anderson Cancer Center in September 2013 to continue this work and to build a program to collect serial biopsies in patients with melanoma and other cancers on targeted therapy and immunotherapy, and to better understand responses to therapy and to develop novel strategies to combat resistance.
          • Kevin Williams, PhD
            Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
            Biography
              Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents.
            • Lori Wirth, MD
              Medical Director, Head and Neck Oncology, Massachusetts General Hospital
              Biography
                Dr. Lori Wirth is Medical Director of Massachusetts General Hospital's Center for Head and Neck Cancers and Associate Professor in Medicine at Harvard Medical School. Dr. Wirth received her BA from Brown University and MD from Columbia's College of Physicians and Surgeons. She trained at New York Presbyterian Hospital and Dana-Farber/Harvard Cancer Center. Dr. Wirth is an authority in advanced thyroid cancer and head and neck oncology, with expertise new therapies for head and neck and thyroid cancers. Her research focuses on clinical trials and leveraging translational data to maximize the impact of trial outcomes. In addition to overseeing the Center for Head and Neck Cancers, Dr. Wirth co-directs Mass General/Mass Eye and Ear's Advanced Thyroid Cancer Clinic. Dr. Wirth is Immediate Past Chairperson of the International Thyroid Oncology Group, and sits on a number of national and international oncology committees, including NCCN's Thyroid Committee and ABIM's Medical Oncology Exam Committee.
              Continuing Education (CME/CE/CEU) Credits

              The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


              Committee

              To download the Program Committee brochure here.


              • David Albala, MD

                Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                See more See less
              • Sharon Geaghan, MD

                Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of ...

                See more See less
              • Josip Blonder, MD

                Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                See more See less
              • Peter Blume-Jensen, MD, PhD

                Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.  From 2001 to 2008 Peter was department head at first Serono, US and ...

                See more See less
              • Fred Russell Kramer, PhD

              • Martin Latterich, PhD

                The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                See more See less
              • Ariel Louwrier PhD

                Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                See more See less
              • Judd Moul, MD, FACS

                Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                See more See less
              • Thomas Polascik, MD

                Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                See more See less
              • Rajan Gupta, MD

                Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                See more See less
              • Antonio Baines, PhD

                Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                See more See less
              • Louise Perkins, PhD

                Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on ...

                See more See less
              • Martin Latterich, PhD

                The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                See more See less
              Help

              General LabRoots Questions

              For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
              Contact us

              Virtual Events and Webinars

              Supported Configurations

              • Operating System Internet Explorer Firefox Chrome Safari
                Vista IE8+ FF10+ Chrome15+
                Windows 7 IE8+ FF10+ Chrome15+
                Windows 8 IE10 FF10+ Chrome15+
                Mac OS X   FF10+ Chrome15+ Safari5.1+
              • Cookie settings: session cookies enabled
              • Browser configuration must have JavaScript enabled
              • Adobe Flash player 10.2 or later

              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

              Internet Connection

              • A minimum of 100Kbps is recommended for audio-only events
              • A minimum of 300Kbps is recommended for speaker on-video events

              Computer Equipment

              • Screen Resolution: Minimum 1024x768
              • Video Card: 65,000 colors minimum
              • Sound card and speakers (or headphones) for hearing webcast in full format
              • Audio Card: 16-bit minimum
              • RAM: 512MB of free RAM

              Firewall Protocol

              • HTTP on port 80 or HTTPS on port 443
              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

              Work-At-Home Attendees

              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

              For A Seamless Experience

              When using a mobile device, FREE Mobile Apps are available:

              - For viewing Webinars:

              - For viewing Virtual Events

              Attendee Guide

              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

              Virtual Event and Webinar Support:

              Continuing Education (CME/CE) Support

              Loading Comments...